Paquinimod-d5-1

Paquinimod-d5-1

• UNSPSC Description: Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice[1][2][3].
• Target Antigen: Isotope-Labeled Compounds; SARS-CoV
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease; Inflammation/Immunology
• Purity: 98.19
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(N(C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])CC)C2=C(C3=C(N(C2=O)C)C=CC=C3CC)O
• Molecular Weight: 355.44
• References & Citations: [1]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.|[2]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.|[3]Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4.|[4]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598.|[5]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported